Company profile: ValiRx
1.1 - Company Overview
Company description
- Provider of oncology therapeutics and diagnostics R&D in the United Kingdom, including VAL 101 that acts to shut down the Bcl-2 gene (a proto-oncogene) and human papilloma virus diagnostic products based on the Nucleosomics platform. Offers an evaluation pipeline for cancer projects, Inaphaea BioLabs cell-based assays in oncology and womenβs health, and a partnering strategy to optimize development, minimize risk, and advance early-stage programs toward clinical development.
Products and services
- Inaphaea BioLabs: A subsidiary offering cell-based assays specializing in oncology and women's health, aiming to improve translation of early drug discovery projects toward clinical development
- Evaluation Pipeline: ValiRX conducts scientific and commercial evaluations of potential cancer projects, mechanisms-of-action-focused, prioritizing disease areas with high potential to identify promising programs
- Partnering Strategy: ValiRX collaborates with external partners to optimize development and minimize risk, early-stage-focused, emphasizing value creation and efficient delivery of development programs
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to ValiRx
FogPharma
HQ: United States
Website
- Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking Ξ²-catenin inhibitor (Phase 1/2), Ξ²-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full FogPharma company profile β
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Arius Research company profile β
Basilea
HQ: Switzerland
Website
- Description: Provider of innovative pharmaceutical products, including Cresemba, an intravenous and oral azole antifungal for invasive aspergillosis and mucormycosis, and Zevtera, an advanced-generation intravenous cephalosporin antibiotic for severe bacterial infections including Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Basilea company profile β
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Immunitas Therapeutics company profile β
Incyte
HQ: United States
Website
- Description: Provider of drug discovery and development focused on building a proprietary pipeline of novel small molecule drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Incyte company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for ValiRx
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ValiRx
2.2 - Growth funds investing in similar companies to ValiRx
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for ValiRx
4.2 - Public trading comparable groups for ValiRx
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β